Another 'Practice-Changing' Study in High-Risk Bladder Cancer

abdulmanannet77@gmail.comOctober 17, 2025

0 1 Less than a minute

https://www.profitableratecpm.com/f4ffsdxe?key=39b1ebce72f3758345b2155c98e6709c

Another 'Practice-Changing' Study in High-Risk Bladder Cancer (MedPage Today) — BERLIN — Adding durvalumab (Imfinzi) to bacillus Calmette-Guérin (BCG) induction and maintenance therapy significantly improved disease-free survival (DFS) in patients with BCG-naive, high-risk non-muscle-invasive bladder…